Find out on how categorizing a drug as a brand or a generic is integral to a PBM's determination of its payment formulas and performance guarantees as well as what pharmaceutical payers can do to avoid potential mischaracterizations. (PRWeb May
LegalView informed readers of its newest information portal detailing the U.S. Food and Drug Administration (FDA) ordered recall of the Digitek-brand digoxin heart tablets. The tablets had been recently discovered to have been manufactured containing twice the amount of active
Glenn Leman, President and Brendan Leonard, Senior Director of Sales & Marketing, attended a White House ceremony on Tuesday during which President George W. Bush presented the "E" Award for Excellence in Exporting to Health Enterprises, Inc. (PRWeb May 22,
Almirall and Forest Laboratories have reported encouraging results from four clinical trials assessing the efficacy and safety of aclidinium bromide, an investigational treatment for chronic obstructive pulmonary disease.
Five Prime Therapeutics and Pfizer have signed a worldwide collaborative research and license agreement, which will focus on the discovery of antibody targets and novel therapeutic protein products to treat certain areas of cancer and diabetes.
GlobeImmune has completed the planned enrollment of 120 subjects in a Phase II clinical trial to evaluate the GI-5005 Tarmogen for the treatment of patients with chronic hepatitis C infection.
Omeros has started patient enrollment for the Phase I study of OMS201, the company's second PharmacoSurgery drug product candidate, for use during urological surgery.
Kai Pharmaceuticals has started enrollment in a Phase I clinical study of KAI-1678, a first-in-class, isozyme-selective inhibitor of the epsilon protein kinase C pathway.
Indevus Pharmaceuticals has reported positive data from Phase III study on Nebido, an investigational, long-acting intramuscular injection for the treatment of hypogonadism.
Telik, a biopharmaceutical company, has initiated two Phase II Telintra studies - one with Telintra tablets in myelodysplastic syndrome and a second with Telintra tablets in cancer patients at risk for chemotherapy-induced neutropenia.
China Sky One Medical has announced that its subsidiary, Heilongjiang Tianlong Pharmaceuticals, has obtained approvals for two new drugs - Oxymetazoline Hydrochloride nasal drops and Taurine eye drops, from the SFDA.
Misonix has signed a three year exclusive distribution and service agreement with privately-held MD International, for the distribution of the SonaStar ultrasonic surgical aspiration system and the BoneScalpel, a bone cutting device.
Ambulatory Services of America has announced the formation of Rosa of Denton, its fourth joint venture to provide outpatient radiation oncology services. Rosa of Denton is a joint venture between Denton Cancer Center and ASA's subsidiary, Radiation Oncology Services of
Oso Biopharmaceuticals Manufacturing has completed the purchase of Catalent Pharma Solutions's Albuquerque, New Mexico sterile injectables manufacturing business.
Lutronic has received FDA clearance to market its Spectra VRM III multiple laser wavelength system. This dual pulse Q-Switched Nd: Yag laser is the feature-laden successor to the Spectra VRM II.
Penwest Pharmaceuticals has signed a development and licensing agreement with Cobalt Laboratories to develop a formulation of an undisclosed compound utilizing Penwest's TIMERx drug delivery technology.
Adolor and GlaxoSmithKline have announced that the FDA has approved Entereg capsules to help patients regain gastrointestinal function earlier following bowel resection surgery.
Tianyin Pharmaceutical has signed over 60 new distribution agreements with a total of 15 regional distributors, including both new and previously contracted distributors.
